Ansell J E, Patel N, Ostrovsky D, Nozzolillo E, Peterson A M, Fish L
Department of Medicine, University of Massachusetts Medical School, Worcester, USA.
Arch Intern Med. 1995 Nov 13;155(20):2185-9.
The management of oral anticoagulation is fraught with difficulties. This study assessed a new model of anticoagulation management regarding the ability, safety, and efficacy of patients to self-monitor and self-adjust the dose of their oral anticoagulants guided by a capillary whole-blood prothrombin time (PT) monitor.
This investigation is a retrospective cohort study of 20 patients compared with 20 matched control patients receiving oral anticoagulation at a tertiary medical institution.
Study patients monitored their PTs 2153 times during a mean interval of 44.7 months compared with 1608 PTs in matched control patients during a mean interval of 42.5 months. Study patients made an average of 11.5 dosage changes per patient, contrasted with 22.7 changes per control patient (P < .001). The PTs in study patients were within the recommended therapeutic range in 88.6% (95% confidence interval, 87.2 to 89.9) of the determinations compared with 68.0% (95% confidence interval, 65.7 to 70.3; P < .001) of the determinations made by the matched control patients. In response to the 2153 PTs, study patients made 67 (3.1%) dosage decisions that were considered incorrect based on physician guidelines. None of these changes led to adverse outcomes. There was no significant difference in complication rates between the two groups.
Results from what is the first long-term study of patient self-monitoring of PTs and self-adjustment of the warfarin sodium dosage for oral anticoagulation suggest that patients can successfully measure their own PTs, adjust their own warfarin dosage, and achieve a degree of therapeutic effectiveness at least as good, if not better than patients managed in an anti-coagulation clinic. Larger, prospective, randomized trials are needed to confirm the efficacy and safety of this new approach to therapy and to assess its cost-effectiveness.
口服抗凝治疗的管理充满困难。本研究评估了一种新的抗凝管理模式,该模式涉及患者在毛细血管全血凝血酶原时间(PT)监测仪的指导下自我监测和自我调整口服抗凝剂剂量的能力、安全性和有效性。
本调查是一项回顾性队列研究,研究对象为20例患者,并与在一家三级医疗机构接受口服抗凝治疗的20例匹配对照患者进行比较。
研究患者在平均44.7个月的时间间隔内监测PT 2153次,而匹配对照患者在平均42.5个月的时间间隔内监测PT 1608次。研究患者平均每人进行11.5次剂量调整,而对照患者平均每人进行22.7次调整(P <.001)。研究患者的PT值在88.6%(95%置信区间,87.2至89.9)的测定中处于推荐治疗范围内,而匹配对照患者的这一比例为68.0%(95%置信区间,65.7至70.3;P <.001)。针对2153次PT测定结果,研究患者做出了67次(3.1%)根据医生指南被认为不正确的剂量决定。这些调整均未导致不良后果。两组之间的并发症发生率无显著差异。
这是第一项关于患者自我监测PT值和自我调整华法林钠口服抗凝剂量的长期研究,结果表明患者能够成功测量自己的PT值,调整自己的华法林剂量,并达到至少与抗凝门诊管理的患者相当甚至更好的治疗效果。需要进行更大规模的前瞻性随机试验,以证实这种新治疗方法的有效性和安全性,并评估其成本效益。